Trial site
Ente Ospedaliero Ospedali Galliera Di Genova
- 14running trials
- 4closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Conditions
- Thalassaemia6 trials
- Colorectal cancer4 trials
- Sickle cell disease4 trials
- Myelodysplastic syndromes2 trials
- Ovarian cancer2 trials
- Prostate cancer2 trials
- Deep vein thrombosis and pulmonary embolism1 trial
- Myeloproliferative neoplasms1 trial
- Phase
- Phase 310 trials
- Phase 27 trials
- Phase 2/32 trials
- Status
- Active, not recruiting6 trials
- Completed4 trials
- Not yet recruiting4 trials
- Recruiting4 trials
- Suspended1 trial
- Lead sponsor
- Agios Pharmaceuticals, Inc.4 trials
- Celgene Corp.2 trials
- A.C.O.M. Advanced Center Oncology Macerata S.r.l.1 trial
- AbbVie1 trial
- Arianna Anticoagulazione Foundation1 trial
- and 10 more
Running trials
Recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Phase 2 Study of Luspatercept in Adults and Adolescents with Alpha (α)-thalassemia
Recruiting
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
Active, not recruiting
Not yet recruiting
Completed
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Myelodysplastic syndromes2 recruiting
- Sickle cell disease2 recruiting
- Thalassaemia2 recruiting
- Colorectal cancer1 recruiting
- Deep vein thrombosis and pulmonary embolism1 recruiting
- Myeloproliferative neoplasms1 recruiting
- Ovarian cancer1 recruiting
- Prostate cancer1 recruiting
Closed trials
Completed
Active, not recruiting
Completed
Research Study Investigating How Well NDec Works in People With Sickle Cell Disease
Completed
Site data: EU CTIS (euclinicaltrials.eu)Updated 15 Nov 2026